TY - JOUR T1 - Efficacy and safety of grazoprevir/elbasvir +/- RBV for 12 weeks in patients with HCV G1 or G4 infection who previously failed peginterferon/RBV: C-EDGE treatment-experienced trial [P0886] JF - J Hepatol Y1 - 2015 A1 - P Y Kwo A1 - E J Gane A1 - Peng, C-Y A1 - et, al VL - 62 SP - S674-S675 IS - Suppl 2 ER -